Pyxis Oncology gets an upgrade to Outperform from William Blair
Pyxis Oncology moved up to Outperform at William Blair, according to TradingView. Recent notes from three other brokers carry targets of $7 to $8.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, William Blair raised its rating on Pyxis Oncology shares from Market Perform to Outperform. Reference data in the report was supplied by Benzinga.
The three latest analyst notes over the past month came from HC Wainwright & Co., RBC Capital and Wedbush. HC Wainwright reaffirmed a Buy rating with an $8 target on November 20, while RBC and Wedbush kept Outperform ratings with a $7 target on November 6. Across these notes, targets sit between $7 and $8.
why it matters
Rating changes of this kind usually affect only the stock in question and rarely move the broader market. For Pyxis Oncology investors, the recent notes lean positive, but they do not by themselves signal where the shares will trade next.
tags
instruments
sources
- William Blair upgrades Pyxis Oncology to Outperform from Market Perform — TradingView, 20 November 2026 at 12:26 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗